Application of bioregulating therapy in complex treatment of temporomandibular joint diseases in people of elderly and senile age

Iordanishvili AK, Samsonov VV, Soldatova LN, et al. · Advances in Gerontology (Uspekhi Gerontologii)

Pain resolved at 10.3±2.5 days on Sigumir against 12.7±2.9 days in controls, and the joint's clicking and crunching at 17.1±2.7 days against 18.3±3.7; no between-group test is reported for either, and the ranges overlap. On every other objective measure the paper states that no statistically significant difference from the control group was obtained, which it attributes to the preparation acting selectively on cartilage. Over 12 months treatment failed in 2 of 38 (5.2%) on Sigumir and 3 of 24 (12.5%) controls, with relapse in 2 controls (8.3%).

Population

62 elderly and senile Russian patients with temporomandibular arthrosis, arthrosis-arthritis or joint dysfunction, split into 38 given Sigumir and 24 controls

Intervention

Sigumir, one capsule twice a day for a month, added to dental prosthetic work, functional therapy and pharmacotherapy

Comparator

The same prosthetic work, functional therapy and pharmacotherapy without Sigumir, in 24 concurrent patients, so the peptide is the only difference between the groups

Limitations

Allocation is by the treatment a patient received rather than randomised, there is no blinding, and the two timing differences favouring Sigumir carry no between-group test on standard deviations that overlap. The paper's own position is that nothing else separated. Russian-language journal tied to the Khavinson institute.